{"disease":{"id":"stroke","name":"Stroke","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":154},"drugs":{"marketed":[{"drug_id":"edoxaban","indication_name":"Stroke risk reduction in NVAF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"edoxaban","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"chembl-chembl48361","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"dabigatran","indication_name":"Prevention of stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"dabigatran-etexilate-de","indication_name":"Prevention of stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"xarelto","indication_name":"Prevention of stroke caused by a clot in a blood vessel in the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"edaravone","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Radicava","generic_name":"EDARAVONE","company_name":"Kk Bcj-94","drug_phase":"marketed","molecular_target":"","drug_class":"edaravone","quality_score":51,"revenue":null,"mechanism":"Radicava works by scavenging free radicals and reducing oxidative stress in the body."},{"drug_id":"butylphthalide","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"3-Butylphthalide","generic_name":"Butylphthalide","company_name":"CSPC Ouyi Pharmaceutical","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 2","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"rivaroxaban","indication_name":"Prevention of stroke caused by a clot in a blood vessel in the brain","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"dabigatran-etexilate","indication_name":"Prevention of stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"prazosin-hcl","indication_name":"Reducing the risk of stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-07976016-formulation-a","indication_name":"Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07976016 Formulation A","generic_name":"pf-07976016-formulation-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo Retriever 3D","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Trevo XP ProVue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Catheter with Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate","indication_name":"Reduction of stroke and systemic embolism risk in non-valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter and Xtreem Micro Guidewire and Xtreem Micro Catheter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"olmesartan","indication_name":"strokes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"hctz","indication_name":"stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alteplase","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"aprocitentan","indication_name":"Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tryvio","generic_name":"APROCITENTAN","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure."},{"drug_id":"clopidogrel","indication_name":"Prevention of blood clots after heart attack or stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"radicava","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Radicava","company_name":"Shanghai Auzone Biological Technology Co., Ltd.","drug_phase":"marketed","molecular_target":"Polyunsaturated fatty acid lipoxygenase ALOX15","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"activase","indication_name":"Ischemic stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Activase","company_name":"Medical College of Wisconsin","drug_phase":"discontinued","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"non-intervention","indication_name":"Acute Ischemic Stroke (Mechanical Thrombectomy) - Xtreem Micro Guidewire with Xtreem Micro Catheter and Xtreem Micro Guidewire","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non intervention","generic_name":"non-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"technetium-tc-99m-exametazime","indication_name":"Detection of altered cerebral perfusion in stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceretec","generic_name":"TECHNETIUM TC 99M EXAMETAZIME","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"aspirin-and-dipyridamole","indication_name":"Stroke prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"aspirin and dipyridamole","company_name":"UMC Utrecht","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1269025","indication_name":"Reduction of stroke and SE in NVAF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"EDOXABAN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null}],"pipeline":[{"drug_id":"antiplatelet-drug","indication_name":"Ischemic Stroke","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Antiplatelet Drug","generic_name":"antiplatelet-drug","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"oral-anticoagulant","indication_name":"Cryptogenic ischemic stroke with patent foramen ovale (PFO)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."},{"drug_id":"oral-anticoagulant","indication_name":"Secondary stroke prevention in older adults","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":124,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT04072120","title":"Stroke Survival in Municipalities: Impact of Geographic Proximity to First- and Second-degree Relatives","phase":"","overall_status":"UNKNOWN","enrollment_count":7400000,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT07247669","title":"Evaluation and Optimization of Telephone Triage Using Artificial Intelligence (AI) Models for the Detection of Demands for Time-dependent Pathology at the Emergency and Urgent Care Coordination Center (CCUE).","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000000,"lead_sponsor_name":"Centro de Emergencias Sanitarias 061 Andalucía","has_results":false},{"nct_id":"NCT03694392","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","phase":"","overall_status":"COMPLETED","enrollment_count":2776278,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT07135310","title":"STROKE 120 ACTION Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1696000,"lead_sponsor_name":"Shanghai Minhang Central Hospital","has_results":false},{"nct_id":"NCT04002700","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","phase":"","overall_status":"COMPLETED","enrollment_count":1234412,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04878497","title":"Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty","phase":"","overall_status":"UNKNOWN","enrollment_count":1000000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02635685","title":"Clinical Decision Support for Stroke Prevention in Atrial Fibrillation","phase":"NA","overall_status":"UNKNOWN","enrollment_count":442105,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT03939624","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","phase":"","overall_status":"COMPLETED","enrollment_count":419734,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT03596502","title":"Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)","phase":"","overall_status":"COMPLETED","enrollment_count":402764,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT02550717","title":"Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)","phase":"","overall_status":"COMPLETED","enrollment_count":398158,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04934020","title":"Global Impact of the COVID 19 Pandemic on Stroke Care, Cerebral Venous Thrombosis, and Subarachnoid Hemorrhage","phase":"","overall_status":"COMPLETED","enrollment_count":345089,"lead_sponsor_name":"Boston Medical Center","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04775836","title":"An EHR-based Platform To Facilitate Outcomes and Research Methods in Cerebrovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":300000,"lead_sponsor_name":"Ministry of Science and Technology of the People´s Republic of China","has_results":false},{"nct_id":"NCT03167346","title":"The Investigation of Public Awareness of Core Stroke Symptoms","phase":"","overall_status":"COMPLETED","enrollment_count":243279,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06098066","title":"Decoding Risks and Rewards in Ischemic Stroke Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":204411,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT04487340","title":"Computer-based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07130968","title":"Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT05395351","title":"Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization","phase":"","overall_status":"COMPLETED","enrollment_count":113035,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04097912","title":"Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06816238","title":"Smart Education for MACE Prevention and Early Detection","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":87376,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03453073","title":"Chocolate and CVD Risk in Postmenopausal Women","phase":"","overall_status":"COMPLETED","enrollment_count":83310,"lead_sponsor_name":"Brooklyn College of the City University of New York","has_results":false},{"nct_id":"NCT05086874","title":"Using Real-world Evidence to Analyze the Clinical Effects and Adverse Events of Butylphthalide in Stroke Patients","phase":"","overall_status":"COMPLETED","enrollment_count":81292,"lead_sponsor_name":"Xin Huang","has_results":false},{"nct_id":"NCT04545437","title":"The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT07052656","title":"Risk Factors and Outcomes in Patients Treated in Neurocritical Care","phase":"","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03259373","title":"IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation","phase":"NA","overall_status":"COMPLETED","enrollment_count":64666,"lead_sponsor_name":"Harvard Pilgrim Health Care","has_results":true},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT03220568","title":"Adipose Tissue Content of Fatty Acids Present in Dairy Fat and Risk of Stroke. The Danish Diet, Cancer and Health Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06628817","title":"The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":55000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05779215","title":"Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03723382","title":"Stroke in Egyptian Clinical REgisTry","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Society of Minimally Invasive Neurological Therapeutic Procedures","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04584645","title":"A Digital Flu Intervention for People With Cardiovascular Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":49138,"lead_sponsor_name":"Evidation Health","has_results":true},{"nct_id":"NCT03934957","title":"Hamburg City Health Study - a German Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":45000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT04290494","title":"Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;","phase":"","overall_status":"COMPLETED","enrollment_count":42188,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04994756","title":"Stroke Thrombectomy and Aneurysm Registry","phase":"","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT01468701","title":"GLORIA-AF Registry Program - Second and Third Phases","phase":"","overall_status":"COMPLETED","enrollment_count":37235,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT07428382","title":"Development and Validation of Care Pathway Quality Indicators for Stroke and Chronic Coronary Syndrome Using French Administrative Healthcare Database (DELIQUA-CNV)","phase":"","overall_status":"COMPLETED","enrollment_count":36250,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT03119116","title":"Use of Direct Oral Anticoagulants in UK","phase":"","overall_status":"COMPLETED","enrollment_count":31336,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT04199663","title":"Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction","phase":"","overall_status":"COMPLETED","enrollment_count":30191,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06387875","title":"Cohort in Qianwan New District, Ningbo","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT00342992","title":"Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study","phase":"","overall_status":"COMPLETED","enrollment_count":29133,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03218020","title":"Red Meat, Increased Iron Load and CVD Risk","phase":"","overall_status":"COMPLETED","enrollment_count":25540,"lead_sponsor_name":"German Cancer Research Center","has_results":false},{"nct_id":"NCT06548737","title":"Clinical Outcomes Following Primary Intracerebral Hemorrhage","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06707987","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":23250,"lead_sponsor_name":"Supergene, LLC","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}